Expression of NRP-1 and NRP-2 in Endometrial Cancer
-
Published:2019-04-30
Issue:3
Volume:20
Page:254-260
-
ISSN:1389-2010
-
Container-title:Current Pharmaceutical Biotechnology
-
language:en
-
Short-container-title:CPB
Author:
Oplawski Marcin1, Dziobek Konrad1, Grabarek Beniamin2, Zmarzły Nikola2, Dąbruś Dariusz3, Januszyk Piotr3, Brus Ryszard4, Tomala Barbara3, Boroń Dariusz3
Affiliation:
1. Department of Gynecology and Obstetrics with Gynecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Krakow, Poland 2. Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Katowice, Poland 3. Faculty of Health Science, Public Higher Medical Professional School in Opole, Opole, Poland 4. Department of Nurse, High School of Strategic Planning, Koscielna 6, 41-303, Dabrowa Gornicza, Poland
Abstract
Background:Neuropilins (NRPs) participate in many processes related to cancer development such as angiogenesis, lymphangiogenesis and metastasis. Although endometrial cancer is one of the most common gynecological cancers, it has not been studied in terms of NRPs expression.Objective:The aim of this study was to investigate the potential utility of NRPs as important factors in the diagnosis and treatment of endometrial cancer.Methods:Our study consisted of 45 women diagnosed with endometrial cancer at the following degrees of histological differentiation: G1, 17; G2, 15; G3, 13 cases. The control group included 15 women without neoplastic changes. The immunohistochemical reactions were evaluated using light microscopy.Results:We did not detect the expression of NRP-1 and NRP-2 in the control group. NRP-1 expression was found exclusively in cancer cells. It was higher in G2 and G3 and reached about 190% of G1. NRP-2 expression was observed in the endothelium and was similar across all three cancer grades. In cancer cells, NRP-2 expression increased with the degree of histological differentiation.Conclusion:NRP1 and NRP2 are candidates for complementary diagnostic molecular markers and promising new targets for molecular, personalized anticancer therapies.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology
Reference38 articles.
1. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Cell, Neuropilin is a semaphorin III receptor., 1997, 90, 753-762, 2. Chen H, Chédotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuron, Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III., 1997, 19, 547-559, 3. Gaur P, Bielenberg DR, Samuel S, Bose D, Zhou Y, Gray MJ, Dallas NA, Fan F, Xia L, Lu J, Ellis LM. Clin Cancer Res, Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis., 2009, 15, 6763-6770, 4. Grandclement C, Borg C. Cancers (Basel), Neuropilins: A new target for cancer therapy., 2011, 3, 1899-1928, 5. Winberg ML, Noordermeer JN, Tamagnone L, Comoglio PM, Spriggs MK, Tessier-Lavigne M, Goodman CS. Cell, Plexin A is a neuronal semaphorin receptor that controls axon guidance., 1998, 95, 903-916,
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|